Clinical trial NCT01052194 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo, vx-509, vx-509, vx-509, vx-509
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F, CC[C@@](C)(NC1=CC=NC(=N1)C1=CNC2=NC=CC=C12)C(=O)NCC(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects must have been diagnosed with RA as defined by the ACR revised criteria
             with disease duration of at least 6 months from confirmed diagnosis

          -  Subjects must have a swollen joint count of ≥6 out of 28 joints and tender joint count
             of ≥6 out of 28 joints. Joints that have had prior surgery are to be excluded from the
             joint count.

          -  Baseline CRP level must be 1.5 times greater than the upper limit of normal at
             Screening.

          -  Subjects must have failed at least 1 nonbiologic DMARD for any reason.

          -  Subjects may have previously failed no more than 1 biologic DMARD and discontinued
             treatment for reasons other than inadequate response. Subjects must not have been
             treated with Rituximab previously.

          -  Subjects must be willing to comply with contraception requirements.

        Exclusion Criteria:

          -  Subjects with inflammatory rheumatological disorders other than RA.

          -  History or evidence of a clinically significant disorder other than RA (including but
             not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or
             psychiatric disorders), condition or disease that, in the opinion of the investigator
             and medical monitor, would pose a risk to subject safety or interfere with the study
             evaluation, procedures, or completion.

          -  Subjects with clinically important abnormalities in screening physical examination or
             in screening laboratory test results (including the presence of either hepatitis B
             surface antigen, hepatitis C virus antibody, or HIV types 1 -- Subjects with elevation
             in alanine aminotransferase or aspartate aminotransferase above the upper limit of
             normal.

          -  History of hematologic disorders including neutropenia and thrombocytopenia.

          -  Subjects with an acute or chronic active infection requiring systemic antimicrobial
             treatment, or subjects who are at high risk of developing an infection due to a
             compromised immune system. Antifungals for onychomycosis or low-dose antibiotics for
             rosacea, that are not inhibitors or inducers of CYP3A, will be allowed.

          -  Subjects who require concomitant use of any inhibitors or inducers of cytochrome P450
             (CYP) 3A.

          -  Subjects who have been treated with intra-articular injections of corticosteroids
             within 28 days prior to Day 1.

          -  Subjects who have planned major surgery (e.g., joint replacement) or any procedures
             during the study.

          -  Have received any live, attenuated vaccinations within 1 month prior to study drug
             administration.

          -  History of drug or alcohol abuse or excessive alcohol as determined by the
             investigator, during the last 12 months before the screening visit.

          -  History of TB infection of any kind (pulmonary or extrapulmonary, active or latent),
             regardless of history of anti-TB treatment.